Filing Details

 

 

CUSIP No. 873147102		13D

1.		NAMES OF REPORTING PERSONS   Medical Marijuana, Inc.
2.		CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP (see instructions) (a)  [   ] (b)  [   ]
3.		SEC USE ONLY
4.		SOURCE OF FUNDS (see instructions)   OO
5.		CHECK BOX IF DISCLOSURE OF LEGAL PROCEEDINGS IS REQUIRED PURSUANT TO ITEMS 2(d) or 2(e)  [   ]
6.		CITIZENSHIP OR PLACE OF ORGANIZATION   Oregon
NUMBER OF SHARES BENEFICIALLY OWNED BY EACH REPORTING PERSON WITH			7.		SOLE VOTING POWER   20,342,076
			8.		SHARED VOTING POWER   0
			9.		SOLE DISPOSITIVE POWER   20,342,076
			10.		SHARED DISPOSITIVE POWER   0
11.		AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON   20,342,076
12.		CHECK BOX IF THE AGGREGATE AMOUNT IN ROW (11) EXCLUDES CERTAIN SHARES (see instructions)  [   ]
13.		PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW (11)   29.1%
14.		TYPE OF REPORTING PERSON (see instructions)   CO

 

 

 

ITEM 1. SECURITY AND ISSUER

 

This statement on Schedule 13D (“Schedule 13D”) relates to the common stock, par value $0.0001 per share (the “Common Stock”) of TYG Solutions Corp., a Delaware corporation (the “Issuer”).  The address of the principal executive offices of the Issuer is 3805 Old Easton Road, Doylestown, Pennsylvania 18902.

 

ITEM 2. IDENTITY AND BACKGROUND

 

(a)This statement is filed by Medical Marijuana, Inc., an Oregon corporation (the “Reporting Person”). 

(b)The Reporting Person’s address is: 12255 Crosthwaite Circle, Poway, CA 92064. 

(c)The Reporting Person is not an officer and director of Issuer. 

(d)The Reporting Person has not been convicted in a criminal proceeding (excluding traffic violations or similar misdemeanors) during the last five years. 

(e)The Reporting Person has not been a party to a civil proceeding of a judicial or administrative body resulting in a judgment, decree or final order enjoining future violations of, or prohibiting or mandating activities subject to, federal or state securities laws, or finding any violation with respect to such laws. 

(f)The Reporting Person is an Oregon corporation. 

 

ITEM 3. SOURCE AND AMOUNT OF FUNDS OR OTHER CONSIDERATION

 

On July 25, 2018, the Issuer entered into a Share Exchange Agreement (the “Share Exchange”) with Kannalife Sciences, Inc., a Delaware corporation (“Kannalife”) and certain stockholders of Kannalife (the “Kannalife Stockholders”), including Reporting Person, whereby Reporting Person exchanged its shares in Kannalife for 20,342,076 shares of Common Stock of the Issuer.

 

ITEM 4. PURPOSE OF TRANSACTION

 

The purpose of this Schedule 13D is to report the acquisition of 20,342,076 shares of Common Stock by the Reporting Person.  In addition, Reporting Person holds 75 shares of the Company’s Series B Convertible Preferred Stock.  Each share of Series B Convertible Preferred Stock is convertible into and has voting rights equal to 1,000 shares of Common Stock.

 

The Common Stock held by the Reporting Person was acquired for investment purposes in the ordinary course of Reporting Person’s business or investment activities, as the case may be.

 

The Reporting Person may acquire additional Common Stock, dispose of all or some of the Common Stock from time to time, in each case in open market or private transactions, block sales or purchases or otherwise, or may continue to hold the Common Stock, depending on business and market conditions, its continuing evaluation of the business and prospects of the Issuer and other factors.

 

Except to the extent the foregoing may be deemed a plan or proposal, the Reporting Person has no present plan or proposal which relates to, or could result in, any of the events referred to in paragraphs (a) through (j), inclusive, of Item 4 of Schedule 13D. The Reporting Person may, at any time and from time to time, review or reconsider his position and/or change his purpose.

 

ITEM 5. INTEREST IN SECURITIES OF THE ISSUER

 

(a)The aggregate number of shares of Common Stock to which this Schedule 13D relates is 20,342,076 shares.  The Common Stock represent approximately 29.1% of the common stock outstanding of Issuer as of July 25, 2018.  In addition, the Reporting Person holds 75 shares of the Company’s Series B Convertible Preferred Stock.  Each share of Series B Convertible Preferred Stock is convertible into and has voting rights equal to 1,000 shares of Common Stock. 

 

(b)Reporting Person has sole voting and dispositive power over the shares of common stock and preferred stock in which Reporting Person owns.   

 

(c)See Item 3, above. 

 

(d)Not Applicable. 

 

(e)Not Applicable. 

 

 

ITEM 6. CONTRACTS, ARRANGEMENTS, UNDERSTANDINGS OR RELATIONSHIPS WITH RESPECT TO SECURITIES OF THE ISSUER

 

None.

 

ITEM 7. MATERIAL TO BE FILED AS EXHIBITS

 

Exhibit 1.   Share Exchange Agreement, dated July 25, 2018.*

 

*Filed as Exhibit 2.1 to the Issuer’s Current Report on Form 8-K with the Securities and Exchange Commission on July 31, 2018 and incorporated by reference herein.

 

SIGNATURE

 

After reasonable inquiry and to the best of my knowledge and belief, I certify that the information set forth in this statement is true, complete and correct.

 

 

August 6, 2018

Date

 

MEDICAL MARIJUANA, INC.

 

By: /s/ Stuart Titus          

Stuart Titus, CEO